Rankings
▼
Calendar
VIR (Vir Biotechnology, Inc.) Stock Financials & Earnings | Market Cap Arena
VIR
Vir Biotechnology, Inc.
Mkt Cap
$1B
Healthcare
·
Biotechnology
·
🇺🇸 United States
·
NASDAQ
Revenue (TTM)
$69M
Net Income (TTM)
-$438M
EPS (TTM)
-$3.16
Free Cash Flow (TTM)
-$392M
Gross Margin
100.0%
Op. Margin
-682.7%
Net Margin
-638.9%
FCF Margin
-571.5%
P/S Ratio (TTM)
20.3x
P/E Ratio (TTM)
—
YoY Rev Growth
-7.6%
Employees
—
Earnings Reports
▶
Q4 2025
Browse All Reports
Quarterly
FY
Revenue & Profitability
Revenue
Gross Profit
Operating Income
Quarter
Revenue
Gross Profit
Op. Income
Q1 23
$63M
-$97M
-$143M
Q2 23
$4M
-$164M
-$215M
Q3 23
$3M
-$142M
-$187M
Q4 23
$17M
-$90M
-$139M
Q1 24
$56M
-$42M
-$80M
Q2 24
$3M
-$102M
-$159M
Q3 24
$2M
-$193M
-$231M
Q4 24
$12M
-$76M
-$117M
Q1 25
$3M
-$115M
-$140M
Q2 25
$1M
-$96M
-$118M
Q3 25
$240K
-$151M
-$173M
Q4 25
$64M
$431M
-$37M
marketcaparena.com
Valuation
P/S Ratio
P/E Ratio
Quarter
P/S
P/E
Q1 23
3.1x
—
Q2 23
2.8x
—
Q3 23
11.7x
—
Q4 23
16.1x
—
Q1 24
17.5x
—
Q2 24
17.6x
—
Q3 24
17.7x
—
Q4 24
18.7x
—
Q1 25
66.7x
—
Q2 25
73.2x
—
Q3 25
82.5x
—
Q4 25
20.3x
—
marketcaparena.com
Operating Cash Flow
Operating Cash Flow
Free Cash Flow
Quarter
Operating CF
Free CF
Q1 23
-$126M
-$133M
Q2 23
-$389M
-$399M
Q3 23
-$156M
-$160M
Q4 23
-$108M
-$109M
Q1 24
-$109M
-$111M
Q2 24
-$78M
-$79M
Q3 24
-$171M
-$174M
Q4 24
-$88M
-$90M
Q1 25
-$78M
-$80M
Q2 25
-$120M
-$123M
Q3 25
-$168M
-$168M
Q4 25
-$26M
-$21M
marketcaparena.com
Capital Expenditures
CapEx
Quarter
CapEx
Q1 23
$7M
Q2 23
$9M
Q3 23
$4M
Q4 23
$2M
Q1 24
$2M
Q2 24
$666K
Q3 24
$2M
Q4 24
$2M
Q1 25
$2M
Q2 25
$3M
Q3 25
$317K
Q4 25
$4M
marketcaparena.com
OpEx vs Revenue Growth (YoY)
Revenue Growth
OpEx Growth
Quarter
Revenue Growth
OpEx Growth
Q1 23
-94.9%
-5.6%
Q2 23
+109.3%
+18.6%
Q3 23
-99.3%
+5.4%
Q4 23
-66.0%
-22.1%
Q1 24
-10.5%
-33.9%
Q2 24
-19.0%
-26.2%
Q3 24
-9.8%
+23.4%
Q4 24
-26.3%
-16.9%
Q1 25
-94.6%
+4.5%
Q2 25
-60.5%
-26.0%
Q3 25
-89.9%
-25.7%
Q4 25
+417.8%
-22.3%
marketcaparena.com
Stock-Based Compensation
SBC ($)
% of Revenue
Quarter
SBC ($)
% of Revenue
Q1 23
$0
0.0%
Q2 23
$0
0.0%
Q3 23
$0
0.0%
Q4 23
$0
0.0%
Q1 24
$0
0.0%
Q2 24
$0
0.0%
Q3 24
$0
0.0%
Q4 24
$16M
128.0%
Q1 25
$14M
463.7%
Q2 25
$12M
1025.6%
Q3 25
$0
0.0%
Q4 25
$23M
35.2%
marketcaparena.com
OpEx Breakdown
R&D
SG&A
Quarter
R&D
SG&A
Q1 23
$158M
—
Q2 23
$168M
—
Q3 23
$145M
—
Q4 23
$109M
—
Q1 24
$100M
—
Q2 24
$105M
—
Q3 24
$195M
—
Q4 24
$106M
—
Q1 25
$119M
—
Q2 25
$98M
—
Q3 25
$151M
$22M
Q4 25
$88M
$24M
marketcaparena.com
Revenue Segments
Contract Revenue
Grant
Collaboration Revenue
Quarter
Contract Revenue
Grant
Collaboration Revenue
Q1 24
$52M
$5M
—
Q2 24
$886K
$2M
$55K
Q1 25
$2M
$1M
—
marketcaparena.com
Revenue by Geography
Non-US
United States
Quarter
Non-US
United States
Q1 25
$2M
$1M
Q4 25
$61M
$310K
marketcaparena.com
War Chest
Cash & Equivalents
Short-Term Investments
Quarter
Cash
Short-term Investments
Total
Q1 23
$825M
$1.4B
$2.3B
Q2 23
$667M
$1.2B
$1.8B
Q3 23
$452M
$1.2B
$1.7B
Q4 23
$242M
$1.3B
$1.5B
Q1 24
$161M
$989M
$1.1B
Q2 24
$297M
$854M
$1.2B
Q3 24
$168M
$746M
$914M
Q4 24
$223M
$682M
$905M
Q1 25
$274M
$528M
$802M
Q2 25
$211M
$395M
$606M
Q3 25
$170M
$336M
$507M
Q4 25
$234M
$229M
$463M
marketcaparena.com
Shares Outstanding
Shares Outstanding
Quarter
Shares (Diluted)
QoQ Change
Q1 23
134M
+0.3%
Q2 23
134M
+0.4%
Q3 23
134M
+0.2%
Q4 23
135M
+0.2%
Q1 24
135M
+0.5%
Q2 24
136M
+0.7%
Q3 24
137M
+0.3%
Q4 24
137M
+0.1%
Q1 25
137M
+0.5%
Q2 25
138M
+0.7%
Q3 25
139M
+0.3%
Q4 25
139M
+0.2%
marketcaparena.com
Revenue Per Employee
Revenue / Employee
Year
Revenue/Employee
Employees
FY 17
—
—
FY 18
—
—
FY 19
$3K
229
FY 20
$206K
327
FY 21
$2M
444
FY 22
$3M
576
FY 23
$147K
587
FY 24
$182K
408
FY 25
$187K
367
marketcaparena.com